Patents Examined by Karen A. Canella
-
Patent number: 11654193Abstract: There are provided, inter alia, compositions and methods for treatment of cancer. The methods include administering to a subject in need a therapeutically effective amount of a Bruton's tyrosine kinase (BTK) antagonist and a ROR-1 antagonist. Further provided are pharmaceutical compositions including a BTK antagonist, ROR-1 antagonist and a pharmaceutically acceptable excipient. In embodiments, the BTK antagonist is ibrutinib and the ROR-1 antagonist is cirmtuzumab.Type: GrantFiled: May 8, 2020Date of Patent: May 23, 2023Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Thomas J. Kipps, Liguang Chen, Bing Cui
-
Patent number: 11648301Abstract: In one aspect, the present invention provides a method for treating cancer comprising tumor cell vaccination in combination with hematopoietic and immune cell transplantation. In some embodiments, the method involves autologous tumor cell vaccination prior to autologous hematopoietic and immune cell transplantation. In another aspect, the present invention provides a method of purifying tumor cells from a subject in preparation for vaccination.Type: GrantFiled: March 21, 2019Date of Patent: May 16, 2023Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Samuel Strober, Alexander Filatenkov
-
Patent number: 11648311Abstract: This invention relates to antibody-albumin nanoparticle complexes comprising albumin, an antibody with binding specificity for a cancer antigen (e.g. panitumumab), and paclitaxel, wherein the nanoparticle complex has been pre-formed in vitro such that the nanoparticle complex has antigen-binding specificity (e.g. EGFR binding specificity), for the purpose of providing cancer (e.g. EGFR-related cancer) treatments in a subject in need thereof.Type: GrantFiled: May 12, 2020Date of Patent: May 16, 2023Assignee: Mayo Foundation for Medical Education and ResearchInventors: Svetomir N. Markovic, Wendy K. Nevala
-
Patent number: 11642400Abstract: The present disclosure encompasses immunogenic/therapeutic compositions including Globo series antigens (SSEA-4, Globo H or SSEA-3) glycoconjugates and therapeutic adjuvants (OBI-821 or OBI-834) as well as methods of making and using the same to treat proliferative diseases such as cancer. The therapeutic conjugates include an antigen linked to a carrier. In particular, the therapeutic conjugates include a SSEA-4, Globo H or SSEA-3 moiety and a KLH moiety subunit linked via a linker. The therapeutic compositions are in part envisaged to act as cancer vaccines (single valent, bi-valent or tri-valent vaccines) for boosting the body's natural ability to protect itself, through the immune system from dangers posed by damaged or abnormal cells such as cancer cells. Exemplary immune response can be characterized by reduction of the severity of disease, including but not limited to, prevention of disease, delay in onset of disease, decreased severity of symptoms, decreased morbidity and delayed mortality.Type: GrantFiled: July 27, 2017Date of Patent: May 9, 2023Assignee: OBI PHARMA, INC.Inventors: Cheng-Der Tony Yu, Peiwen Yu, Kuo-Pao Lai, Wei-Han Lee, I-Ju Chen, Shu-Yi Lin, Yih-Huang Hsieh
-
Patent number: 11633426Abstract: Provided are methods for administering multiple doses of cells, such as T cells, to subjects for cell therapy. Also provided are compositions and articles of manufacture for use in the methods. The cells generally express recombinant receptors such as chimeric receptors, e.g., chimeric antigen receptors (CARs) or other transgenic receptors such as T cell receptors (TCRs). The methods generally involve administering a first and at least one consecutive dose of the cells. Timing of the doses relative to one another, and/or size of the doses, in some embodiments provide various advantages such as lower or reduced toxicity and improved efficacy, for example, due to increased exposure of the subject to the administered cells. In some embodiments, the first dose is a relatively low dose, such as one that reduces tumor or disease burden, thereby improving the efficacy of consecutive or subsequent doses, and the consecutive dose is a consolidating dose.Type: GrantFiled: October 29, 2019Date of Patent: April 25, 2023Assignee: Juno Therapeutics, Inc.Inventor: Mark J. Gilbert
-
Patent number: 11633506Abstract: The disclosed method of treating a malignant solid tumor in a subject includes the steps of administering to the subject an immunomodulatory dose of a radioactive phospholipid ether metal chelate, a radiohalogenated phospholipid ether, or other targeted radiotherapy (TRT) agent that is differentially retained within malignant solid tumor tissue, and either (a) performing in situ tumor vaccination in the subject by introducing into at least one of the malignant solid tumors one or more agents capable of stimulating specific immune cells within the tumor microenvironment, or (b) performing immunotherapy in the subject by systemically administering to the subject an immunostimulatory agent, such as an immune checkpoint inhibitor.Type: GrantFiled: November 10, 2017Date of Patent: April 25, 2023Assignee: WISCONSIN ALUMNI RESEARCH FOUNDATIONInventors: Jamey Weichert, Paul Sondel, Ravi Patel, Zachary Morris, Peter Carlson, Reinier Hernandez, Joseph Grudzinski
-
Patent number: 11623965Abstract: A prodrugged antibody has a blocking moiety attached to a Cys on its heavy or light chain via a linker having a cleavable moiety. The blocking moiety inhibits binding of the antibody to its antigen. Cleavage of the cleavable moiety releases the blocking moiety and restores ability of the antibody to bind to its antigen.Type: GrantFiled: August 14, 2018Date of Patent: April 11, 2023Assignee: Bristol-Myers Squibb CompanyInventors: Stanley R. Krystek, Jr., Yong Zhang, Gregory D. Vite, Arvind Rajpal, Chetana Rao-Naik, Paul E. Morin, Mohan Srinivasan, Zheng Lin, Virginie Lafont, Alla Pritsker
-
Patent number: 11617787Abstract: A method of treating cancer in a subject that includes administering in situ to the cancer a therapeutically effective amount of a plant virus or virus-like particle to the subject.Type: GrantFiled: May 8, 2018Date of Patent: April 4, 2023Assignee: CASE WESTERN RESERVE UNIVERSITYInventors: Nicole F. Steinmetz, Amy M. Wen, Steven Fiering, Patrick H. Lizotte
-
Patent number: 11612643Abstract: Provided are a tumour antigen polypeptide having the amino acid sequence as shown in SEQ ID NO: 2 or a variant thereof; a nucleic acid encoding same; a nucleic acid construct, an expression vector, and a host cell comprising the encoding nucleic acid; and an antigen presenting cell presenting the tumour antigen polypeptide on the cell surface and an immune effector cell thereof. Also provided is the use of the polypeptide, nucleic acid, antigen presenting cell or immune effector cell in the diagnosis, prevention and treatment of cancers.Type: GrantFiled: September 30, 2016Date of Patent: March 28, 2023Assignee: GENOIMMUNE THERAPEUTICS CO, , LTD.Inventors: Bo Li, Geng Liu, Si Qiu, Dongli Li, Chongming Jiang, Shuntao Luo, Xiumei Lin, Ting An, Yong Hou, Chengchi Chao, Zhen Cheng, Handong Li, Naibo Yang
-
Patent number: 11602544Abstract: The disclosure provides immune cells comprising a first activator receptor and a second inhibitory receptor, and methods of making and using same for the treatment of cancer.Type: GrantFiled: May 17, 2022Date of Patent: March 14, 2023Assignee: A2 Biotherapeutics, Inc.Inventors: Julyun Oh, Han Xu, Carl Alexander Kamb
-
Patent number: 11597752Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T-cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.Type: GrantFiled: August 30, 2019Date of Patent: March 7, 2023Assignee: IMMATICS BIOTECHNOLOGIES GMBHInventors: Oliver Schoor, Andrea Mahr, Toni Weinschenk, Anita Wiebe, Jens Fritsche, Harpreet Singh
-
Patent number: 11597775Abstract: The present invention relates to preparations and methods for treating a GD2 positive cancer by administering a preparation comprising a chimeric or humanized anti-GD2 antibody to a patient, wherein the patient is not concomitantly treated with Interleukin-2 (IL-2 wherein a GD2 positive cancer is treated in the patient. Furthermore, the invention relates to preparations and methods for the treatment of a GD2 positive cancer in a patient, wherein a preparation comprising an anti-GD2 antibody is administered to the patient as a continuous infusion, without concomitantly administering IL-2. The present invention further relates to preparations and methods for the treatment of a GD2 positive cancer in a patient, wherein the one or more anti-GD2 antibody treatment periods is/are preceded, accompanied, and/or followed by one or more treatment periods with a retinoid.Type: GrantFiled: November 28, 2017Date of Patent: March 7, 2023Assignee: APEIRON BIOLOGICS AGInventors: Hans Loibner, Oliver Mutschlechner, Ruth Ladenstein, Isabel Klier
-
Patent number: 11559574Abstract: The present invention provides a modified human cancer cell comprising a recombinant polynucleotide encoding an allele of a human leukocyte antigen gene. The present invention also provides methods for selecting a whole-cell cancer vaccine for a subject having cancer and methods of treating cancer using whole-cell cancer vaccines of the present invention. In addition, the present invention provides a method of determining the HER2 status of a cell. Compositions and kits are also provided herein.Type: GrantFiled: August 23, 2018Date of Patent: January 24, 2023Assignee: BriaCell Therapeutics Corp.Inventors: Markus Daniel Lacher, Joseph Paul Wagner, Charles Louis Wiseman, William Valentine Williams
-
Patent number: 11548952Abstract: Provided are methods of clinical treatment of diffuse large B-cell lymphoma (DLBCL) (e.g., relapsed and/or refractory DLBCL eligible for autologous stem cell transplant) in human subjects using a bispecific antibody which binds to CD3 and CD20 in combination with standard of care regimen of R-DHAX/C (rituximab, dexamethasone, cytarabine, and oxaliplatin/carboplatin).Type: GrantFiled: December 22, 2021Date of Patent: January 10, 2023Assignee: GENMAB A/SInventors: Brian Elliott, Tahamtan Ahmadi
-
Patent number: 11535679Abstract: Provided are methods of clinical treatment of follicular lymphoma (for example, relapsed and/or refractory follicular lymphoma) in human subjects using a bispecific antibody which binds to CD3 and CD20 in combination with standard of care regimens of rituximab and bendamustine.Type: GrantFiled: December 21, 2021Date of Patent: December 27, 2022Assignee: GENMAB A/SInventors: Brian Elliott, Tahamtan Ahmadi, Christopher W. L. Chiu, Esther C. W. Breij
-
Patent number: 11525008Abstract: The present invention relates to methods and pharmaceutical compositions for the treatment of lung cancer. The inventors showed that FHIT (also known as bis(5-adenosyl)-triphosphatase) regulates HER2 activity in lung tumor cells and that HER2 inhibitors reduce invasion induced by FHIT inhibition. In particular, the present invention relates to a method of treating lung cancer in a patient in need thereof comprising the steps of i) determining the expression level of FHIT in a tumor tissue sample obtained from the patient, ii) comparing the expression level determined at step i) with a predetermined reference value and iii) administering to the patient a therapeutically effective amount of at least one HER2 inhibitor when the expression level determined at step i) is lower than the predetermined reference level.Type: GrantFiled: September 21, 2017Date of Patent: December 13, 2022Assignees: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), UNIVERSITÉ DE REIMS CHAMPAGNE-ARDENNE, CENTRE HOSPITALIER UNIVERSITAIRE DE REIMSInventors: Béatrice Raby, Amina Jouida, Myriam Polette
-
Patent number: 11517622Abstract: The present invention relates to pharmaceutical compositions and combinations comprising regorafenib or its hydrate, solvate, metabolite or pharmaceutically acceptable salt or a polymorph thereof and a PD-1/PD-L1(2) inhibitor for treating, preventing or managing diseases and conditions including hyperproliferative disorders such as cancer in humans and other mammals.Type: GrantFiled: December 31, 2019Date of Patent: December 6, 2022Assignee: BAYER HEALTHCARE LLCInventors: Sabine Hoff, Lars Rose, Dieter Zopf, Fabian Kiessling, Wiltrud Lederle, Dennis Doleschel
-
Patent number: 11497787Abstract: Novel antibody-drug conjugates (ADCs) and methods of using such ADCs to treat proliferative disorders are described herein. The ADCs may comprise a PARP protein automodified with a plurality of poly-ADP-ribose polymers functionalized with novel NAD+ analogues. The automodified PARP with functionalized poly-ADP-ribose polymers provide a novel type of drug carrier, which allows facile conjugation of monoclonal antibodies and cytotoxic drug in high ratios.Type: GrantFiled: March 27, 2020Date of Patent: November 15, 2022Assignee: University of Southern CaliforniaInventor: Yong Zhang
-
Patent number: 11492412Abstract: A method of treating a high-risk neuroblastoma in a patient is described.Type: GrantFiled: March 3, 2021Date of Patent: November 8, 2022Assignee: APEIRON BIOLOGICS AGInventors: Hans Loibner, Oliver Mutschlechner, Ruth Ladenstein, Isabel Klier
-
Patent number: 11491205Abstract: The present disclosures related to human interleukin-2 (hIL2) muteins, pharmaceutical formulations thereof, methods for preparing interleukin-2 muteins, recombinant vectors and cells comprising nucleic acids encoding IL2 muteins and methods for the treatment of human disease.Type: GrantFiled: January 14, 2021Date of Patent: November 8, 2022Assignee: Synthekine, Inc.Inventors: Jan Emmerich, Steve Kauder, Scott Alan McCauley, Martin Oft